OUTCOMES AT 3 YEARS IN EBV plus EUROPEAN SUBPOPULATIONS FROM BENEFIT AND BENEFIT-EXT

被引：0
|
作者：
Budde, K. [1 ]
Blancho, G. [2 ]
Merville, P. [3 ]
Moal, M. -C. [4 ]
Rostaing, L. [5 ]
Harler, M. B. [6 ]
Grinyo, J. [7 ]
机构：
[1] Charite, D-13353 Berlin, Germany
[2] Univ Hosp Nantes, Nantes, France
[3] CHU Bordeaux, Bordeaux, France
[4] CHU Brest, F-29285 Brest, France
[5] CHU Toulouse, Toulouse, France
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Hosp Univ Bellvitge, Barcelona, Spain
来源：
TRANSPLANT INTERNATIONAL | 2014年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
P030
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [21] Outcomes at Five Years in Black/African-American Kidney Transplant Recipients from the Long-Term Extension of the Belatacept BENEFIT and BENEFIT-EXT Studies
    Florman, S.
    Rice, K.
    Chan, L.
    Zhang, R.
    Abouljoud, M.
    Steinberg, S.
    Pearson, T.
    Pupim, L.
    Vincenti, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 311 - 311
  • [22] Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT
    Florman, Sander
    Vincenti, Flavio
    Durrbach, Antoine
    Abouljoud, Marwan
    Bresnahan, Barbara
    Garcia, Valter Duro
    Mulloy, Laura
    Rice, Kim
    Rostaing, Lionel
    Zayas, Carlos
    Calderon, Kellie
    Meier-Kriesche, Ulf
    Polinsky, Martin
    Yang, Lingfeng
    Pestana, Jose Medina
    Larsen, Christian P.
    CLINICAL TRANSPLANTATION, 2018, 32 (04)
  • [23] ONE YEAR SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT PATIENTS FROM THE BENEFIT AND BENEFIT-EXT STUDIES
    Larsen, C.
    Charpentier, B.
    Grinyo, J. M.
    Medina-Pestana, J. D.
    Vanrenterghem, Y.
    Vincenti, F.
    Thomas, D.
    Di Russo, G. B.
    Shi, R.
    TRANSPLANT INTERNATIONAL, 2009, 22 : 90 - 90
  • [24] One Year Safety Profile of Belatacept in Kidney Transplant Patients from the BENEFIT and BENEFIT-EXT Studies
    Larsen, C.
    Charpentier, B.
    Grinyo, J. M.
    Medina-Pestana, J. D.
    Vanrenterghem, Y.
    Vincenti, F.
    Thomas, D.
    Di Russo, G. B.
    Shi, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 495 - 495
  • [25] Four-Year Outcomes by Donor Type from the Long-Term Extension of the Belatacept BENEFIT and BENEFIT-EXT Studies.
    Durrbach, A.
    Florman, S.
    Zhang, R.
    Becker, T.
    Grinyo, J.
    Lang, P.
    Garcia, V. D.
    Duan, T.
    Pupim, L.
    Medina Pestana, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 407 - 407
  • [26] Cardiovascular Risk Calculator for Renal Transplant Recipients: Applications to BENEFIT and BENEFIT-EXT Trials
    Fellstrom, B.
    Holdas, H.
    Holme, I.
    Jardine, A.
    Soveri, I.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 409 - 410
  • [27] LIMITED IMPACT OF ACUTE REJECTION ON GRAFT OUTCOMES IN BELATACEPT-TREATED KIDNEY TRANSPLANT RECIPIENTS (BENEFIT/BENEFIT-EXT)
    Larsen, C.
    Vincenti, F.
    Grinyo, J. M.
    Charpentier, B.
    Di Russo, G. B.
    Garg, P.
    Dong, Y.
    TRANSPLANT INTERNATIONAL, 2009, 22 : 193 - 193
  • [28] IMPACT OF DONOR AGE ON 3-YEAR OUTCOMES OF EXTENDED CRITERIA DONOR KIDNEY RECIPIENTS IN BENEFIT-EXT
    Lehner, Frank
    Budde, Klemens M. D.
    Morales, Jose M.
    Blancho, Gilles
    Muehlbacher, Ferdinand
    Rice, Kim
    Pupim, Lara
    Aigner, Sigrid
    Vincenti, Flavio
    TRANSPLANT INTERNATIONAL, 2013, 26 : 92 - 92
  • [29] EVALUATION OF DONOR-SPECIFIC ANTIBODIES THROUGH 7 YEARS WITH BELATACEPT: FINAL RESULTS FROM BENEFIT-EXT
    Meier-Kriesche, Herwig-Ulf
    Bray, Robert
    Gebel, Howard
    Townsend, Robert
    Larsen, Christian
    TRANSPLANT INTERNATIONAL, 2015, 28 : 82 - 82
  • [30] THREE YEAR OUTCOMES BY DONOR TYPE IN PHASE III STUDIES OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANTATION (BENEFIT AND BENEFIT-EXT)
    Florman, S.
    Becker, T.
    Bresnahan, B.
    Chevaile-Ramos, A.
    Carvalho, D.
    Muehlbacher, F.
    O'Connell, P.
    Duan, T.
    Agarwal, M.
    Larsen, C.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 51 - 51
12345